Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

First Posted Date
2023-02-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
377
Registration Number
NCT05722015
Locations
🇭🇺

Törökbálinti Tüdőgyógyintézet ( Site 2105), Törökbálint, Pest, Hungary

🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207), Kaohsiung, Taiwan

🇺🇸

St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023), Phoenix, Arizona, United States

and more 107 locations

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

First Posted Date
2023-02-08
Last Posted Date
2023-02-08
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
368
Registration Number
NCT05715840

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

First Posted Date
2023-02-06
Last Posted Date
2024-01-16
Lead Sponsor
Hackensack Meridian Health
Target Recruit Count
108
Registration Number
NCT05715229
Locations
🇺🇸

John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States

🇺🇸

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

🇺🇸

Jersey Shore University Medical Center, Neptune, New Jersey, United States

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

First Posted Date
2023-02-03
Last Posted Date
2024-03-20
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT05711628

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

First Posted Date
2023-01-19
Last Posted Date
2024-03-15
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
28
Registration Number
NCT05691010
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States

and more 4 locations

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

First Posted Date
2023-01-19
Last Posted Date
2024-10-26
Lead Sponsor
Nikolaj Frost MD
Target Recruit Count
136
Registration Number
NCT05689671
Locations
🇩🇪

LungenClinic Großhansdorf GmbH, Großhansdorf, Germany

🇩🇪

Universitätsmedizin Göttingen, Göttingen, Germany

🇩🇪

Asklepios Klinkum Hamburg, Hamburg, Germany

and more 28 locations

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

First Posted Date
2023-01-18
Last Posted Date
2024-12-02
Lead Sponsor
AstraZeneca
Target Recruit Count
1350
Registration Number
NCT05687266
Locations
🇻🇳

Research Site, Ho Chi Minh, Vietnam

DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

First Posted Date
2023-01-13
Last Posted Date
2024-08-19
Lead Sponsor
Fundación GECP
Target Recruit Count
40
Registration Number
NCT05684276
Locations
🇪🇸

Hospital Universitari Vall d' Hebron, Barcelona, Spain

🇪🇸

Hospital Universitario Jerez De La Frontera, Jerez De La Frontera, Cádiz, Spain

🇪🇸

Fundació Althaïa, Manresa, Spain

and more 26 locations

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

First Posted Date
2022-12-27
Last Posted Date
2023-02-24
Lead Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Target Recruit Count
240
Registration Number
NCT05664971
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

First Posted Date
2022-12-16
Last Posted Date
2024-08-16
Lead Sponsor
Mabscale, LLC
Target Recruit Count
620
Registration Number
NCT05654454
Locations
🇷🇺

Smolensk oncologic dispensary, Smolensk, Russian Federation

🇷🇺

Leningrad regional clinical hospital, Saint Petersburg, Russian Federation

🇷🇺

Northwestern Center for Evidence-Based Medicine, Saint Petersburg, Russian Federation

and more 25 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy